Every 8-K that MARIMED INC (MRMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRMD filings page.
MariMed Inc. reported second quarter 2026 revenue of $41.9 million, up from $39.5 million a year earlier, driven by growth in both retail and wholesale product sales. GAAP gross margin was 38.7%, with non-GAAP gross margin of 40.0%.
The company recorded a GAAP net loss of $3.6 million for the quarter compared with a loss of $1.4 million in 2025. Non-GAAP net loss was $2.4 million, versus non-GAAP net income of $0.3 million a year earlier. Non-GAAP Adjusted EBITDA was $3.9 million, down from $4.8 million, and the Adjusted EBITDA margin declined to 9.4% from 12.1%.
For the first six months of 2026, revenue was $81.4 million and net cash provided by operating activities increased to $3.2 million from $1.6 million. As of June 30, 2026, MariMed reported total assets of $197.2 million, cash of $8.4 million, total liabilities of $147.1 million, income taxes payable of $31.5 million, mezzanine equity of $6.9 million and stockholders’ equity of $43.2 million.
MariMed Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. Stockholders re-elected four directors—Jon R. Levine, Edward Gildea, David Allen, and Eva Selhub, M.D.—to serve until the next annual meeting or until successors are elected and qualified.
Stockholders also approved, on an advisory basis, the appointment of M&K CPAs PLLC as MariMed’s independent auditors for the 2026 fiscal year, with a substantial majority of votes cast in favor.
MariMed Inc. reported first-quarter 2026 revenue of $39.5 million, up from $37.9 million a year earlier, driven by both retail and wholesale product sales. GAAP gross margin was 38.7%, with non-GAAP gross margin at 40.1%.
The company posted a GAAP net loss of $3.8 million, improving from a $5.5 million loss in 2025. Non-GAAP net loss was $3.2 million, while non-GAAP Adjusted EBITDA rose to $3.6 million and the Adjusted EBITDA margin increased to 9.1%.
MariMed highlighted a March 2 Restructuring and Exchange Agreement for $14.7 million of Series B convertible preferred stock, replacing a February 2026 mandatory conversion with longer-dated instruments and extending the weighted-average maturity to 4.6 years, which reduces near-term refinancing pressure and supports liquidity.
MariMed Inc. reported fourth quarter and full year 2025 results showing modest revenue growth but lower margins and profitability. Full year revenue was $159.8 million, up slightly from $157.7 million in 2024, while GAAP net loss widened to $14.5 million from $12.4 million. Non-GAAP Adjusted EBITDA was $16.9 million versus $19.3 million, marking a sixth consecutive year of positive Adjusted EBITDA but at a lower margin. In Q4 2025, revenue rose to $41.7 million from $38.9 million, with GAAP gross margin declining to 25%. Management highlighted 11% wholesale revenue growth, distribution reaching 85% of dispensaries in core markets, and leading edible rankings for Betty’s Eddies. The company also restructured $14.725 million of Series B preferred stock, extending the weighted average maturity by 4.6 years to reduce near-term refinancing risk and support liquidity.
MariMed Inc. entered into a restructuring agreement with Navy Capital that cancels its prior Series B preferred stock obligation tied to a potential cash payment of approximately $14.2 million. In its place, MariMed issued two new promissory notes totaling $8,000,000 and new Series B preferred shares.
The notes comprise $2,000,000 due on March 1, 2028 at 8% interest and $6,000,000 due on March 1, 2031 at 10%, with a possible rate reduction if the first note is repaid within six months. MariMed also issued 26,900,000 non-voting New Series B Convertible Preferred shares with a liquidation preference of $6,725,000 that rank senior to common stock for dividends and liquidation and are convertible into common stock under specified price and VWAP conditions.
MariMed Inc. furnished a Form 8-K stating it issued a press release with financial results for the three- and nine-month periods ended September 30, 2025.
The press release is included as Exhibit 99.1 and, under Item 2.02 and General Instruction B.2, is furnished and not deemed filed under the Exchange Act.